Media Release

Copenhagen, Denmark, March 10, 2021

- Two posters featuring innovative Genmab bispecific antibody programs selected for presentation at AACR Annual Meeting 2021

Genmab A/S (Nasdaq: GMAB) announced today that two posters evaluating investigational medicines created using Genmab's DuoBody® technology will be presented at the American Association for Cancer Research Annual Meeting 2021, taking place virtually April 10-15 and May 17-21. The posters summarize data from a preclinical evaluation of the investigational medicine, epcoritamab (DuoBody-CD3xCD20) in combination with standard of care therapies for the treatment of B-cell lymphomas, and a preclinical mechanism of action evaluation of GEN1042 (DuoBody-CD40x4-1BB). The abstracts have been published on the AACR website and may be accessed via the Online Meeting Planner. All e-poster presentations will be made available on the on-demand Virtual Congress platform on www.aacr.org. Epcoritamab is being co-developed by Genmab and AbbVie. GEN1042 is being co-developed by Genmab and BioNTech.

"We are excited to present data showcasing the progress we are making with key investigational medicines in our product pipeline utilizing the innovative DuoBody bispecific antibody platform," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "Together with our partners, we continue to employ the DuoBody technology platform to effectively create opportunities for innovative antibody drug design and development with the goal of transforming cancer treatment."

**Epcoritamab (DuoBody-CD3xCD20):**
Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas

**GEN1042 (DuoBody-CD40x4-1BB):**
DuoBody-CD40x4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functions in vitro by conditional CD40 and 4-1BB agonist activity

**About Epcoritamab**
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells.\(^1\) CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.\(^2\) Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration.

**About GEN1042 (DuoBody-CD40x4-1BB)**
GEN1042 (DuoBody-CD40x4-1BB) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody format.
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.

Contact:
Marisol Peron, Senior Vice President, Global Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®.